Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead's China Remdesivir Patents Confirmed, Generics Firms Cautioned

US Firm Gains Upper Hand Amid Patent Dispute

Executive Summary

As the front-runner antiviral in the fight against the coronavirus gets increasingly positive attention in China, officials take action to keep the originator front and center and domestic copycats at bay.

You may also be interested in...



Hetero Head On Remdesivir Partnering, Royalty Model

Hetero is one of the new licensees for Gilead’s remdesivir, the investigational antiviral in the spotlight as a potential treatment for COVID-19, and the Indian group’s managing director shares insights on its supply chain readiness and the royalty model of the deal.

Biogen Still Not Disclosing Which Exec Has Coronavirus Infection

Public health officials in Massachusetts say Biogen company meeting is source of 70 cases in the state.

From China With Discount? BeiGene Moves Towards First Global PD-1 Green Light

Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel